{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:51:10Z","timestamp":1760644270003},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2001,11]]},"DOI":"10.1016\/s0009-9120(01)00272-7","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T10:21:15Z","timestamp":1027592475000},"page":"635-638","source":"Crossref","is-referenced-by-count":28,"title":["Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS\/MS"],"prefix":"10.1016","volume":"34","author":[{"given":"Margarida F.B","family":"Silva","sequence":"first","affiliation":[]},{"given":"J","family":"Selhorst","sequence":"additional","affiliation":[]},{"given":"Henk","family":"Overmars","sequence":"additional","affiliation":[]},{"given":"Albert H","family":"van Gennip","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Maya","sequence":"additional","affiliation":[]},{"given":"Ronald J.A","family":"Wanders","sequence":"additional","affiliation":[]},{"given":"Isabel Tavares","family":"de Almeida","sequence":"additional","affiliation":[]},{"given":"Marinus","family":"Duran","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0009-9120(01)00272-7_BIB1","series-title":"Milestones in drug therapy - valproate","first-page":"91","article-title":"Toxicity","author":"Radatz","year":"1999"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/gut.37.1.140","article-title":"Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity","volume":"37","author":"Kr\u00e4henbul","year":"1995","journal-title":"Gut"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF01377353","article-title":"Decreased serum carnitine in valproate-induced Reye-syndrome","volume":"139","author":"B\u00f6hles","year":"1982","journal-title":"Eur J Ped"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB4","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3476(82)80320-X","article-title":"Carnitine deficiency and hyperammonemia associated with valproic acid therapy","volume":"101","author":"Ohtani","year":"1982","journal-title":"J Pediatr"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1528-1157.1986.tb03584.x","article-title":"Serum carnitine during valproic acid therapy","volume":"27","author":"Laub","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1055\/s-2008-1071456","article-title":"L-Carnitine replacement therapy in chronic valproate treatment","volume":"21","author":"Melegh","year":"1990","journal-title":"Neuropediatr"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1528-1157.1993.tb02396.x","article-title":"Carnitine disposition before and during valproate therapy in patients with epilepsy","volume":"34","author":"Riva","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB8","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1212\/WNL.43.11.2362","article-title":"Impaired fatty acid oxidation in children on valproic acid and the effect of L-carnitine","volume":"43","author":"Kossak","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0022-3476(05)81711-1","article-title":"Hepatotoxic effects in a child receiving valproate and carnitine","volume":"123","author":"Murphy","year":"1993","journal-title":"J Pediatr"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1528-1157.1990.tb05387.x","article-title":"Collaborative group for the study of epilepsy. Valproate, carnitine metabolism and biochemical indicators of liver function","volume":"31","author":"Beghi","year":"1990","journal-title":"Epilepsia"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB11","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1345\/aph.19242","article-title":"The role of carnitine supplementation during valproic acid therapy","volume":"34","author":"Raskind","year":"2000","journal-title":"Ann Pharmacotherapy"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB12","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1528-1157.1998.tb01315.x","article-title":"L-carnitine supplementation in childhood epilepsy","volume":"39","author":"De Vivo","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1203\/00006450-199206000-00002","article-title":"Urinary medium-chain acyl-CoA dehydrogenase deficiency, medium-chain triglyceride feeding and valproic acid therapy","volume":"31","author":"Schmidt-Sommerfeld","year":"1992","journal-title":"Pediatr Res"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB14","first-page":"318","article-title":"Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, carbamazepine in children","volume":"123","author":"Hug","year":"1991","journal-title":"J Pediatr"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1023\/A:1005587617745","article-title":"Quantitative plasma acylcarnitine analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidaemias and fatty acid oxidation defects","volume":"22","author":"Vreken","year":"1999","journal-title":"J Inher Metab Dis"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/clinchem\/46.5.727","article-title":"Assay for free and total carnitine in human plasma using using electrospray tandem mass spectrometry","volume":"46","author":"Stevens","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1006\/mgme.1999.2911","article-title":"Recent developments in the investigation of inherited metabolic disorders using cultured human cells","volume":"68","author":"Roe","year":"1999","journal-title":"Molec Genet Metab"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2165\/00003495-199447020-00008","article-title":"Valproic acid","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB19","first-page":"12,404","article-title":"Improved procedure for simultaneous determination of sodium valproate and ethosuximide in serum by gas liquid chromatography","volume":"41","author":"Bousquet","year":"1986","journal-title":"Farmaco"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB20","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1542\/peds.101.5.e9","article-title":"Valproate therapy does not deplete carnitine levels in otherwise healthy children","volume":"101","author":"Hirose","year":"1998","journal-title":"Pediatr"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB21","series-title":"Milestones in drug therapy-valproate","first-page":"47","article-title":"Chemistry and biotransformation","author":"Abbott","year":"1999"},{"key":"10.1016\/S0009-9120(01)00272-7_BIB22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1006\/mgme.2001.3200","article-title":"Valproate induces in vitro accumulation of long-chain fatty acyl-carnitines","volume":"73","author":"Silva","year":"2001","journal-title":"Molec Gen and Metab"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912001002727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912001002727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T07:48:01Z","timestamp":1620114481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912001002727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["S0009912001002727"],"URL":"https:\/\/doi.org\/10.1016\/s0009-9120(01)00272-7","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}